M&A / Korean Celltrion Makes First Big Global Move with Acquisition of Takeda APAC Assets
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea,…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on the future role of precision medicine, and the current hurdles impeding its widespread adoption. The pandemic, while tragic, has provided Korean bio-ventures with opportunities to develop and mature What…
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae…